Compare COCO & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCO | DYN |
|---|---|---|
| Founded | 2004 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 2021 | 2020 |
| Metric | COCO | DYN |
|---|---|---|
| Price | $53.77 | $18.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $58.13 | $37.00 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 04-29-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.60 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.12 | N/A |
| Revenue Next Year | $11.40 | N/A |
| P/E Ratio | $46.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.79 | $7.01 |
| 52 Week High | $61.39 | $25.00 |
| Indicator | COCO | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 58.28 |
| Support Level | $50.40 | $18.32 |
| Resistance Level | $55.43 | $20.08 |
| Average True Range (ATR) | 2.49 | 1.18 |
| MACD | -0.31 | 0.10 |
| Stochastic Oscillator | 32.98 | 76.48 |
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.